News
  Date Title View
May 27, 2014
BURLINGTON, Mass., May 27, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present an overview of the company at the 2014 Jefferies Healthcare Conference. Dr. Clayman's presentation is scheduled for June 2, 2014, at 10:30 a.m. Eastern Time. The conference will take place June 2-...
May 8, 2014
Key HighlightsCompleted enrollment of FX006 Phase 2a synovial fluid pharmacokinetics clinical trial with topline data expected in Q2 2014Initiated confirmatory FX006 Phase 2b clinical trial to determine an optimal safe and efficacious dose compared to placebo Added key personnel in Quality Assurance and Regulatory Affairs Significantly bolstered ca...
May 1, 2014
BURLINGTON, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its first quarter 2014 financial results on Thursday, May 8, 2014, at 4:30 p.m. ET. The dial-in number for the conference call is toll-free (855) 770-0022 for domestic participants...
Apr 30, 2014
BURLINGTON, Mass., April 30, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that the first patient has been dosed in a confirmatory Phase 2b clinical trial designed to further evaluate the safety, tolerability and efficacy of certain doses of FX006 as a treatment for relieving pain associated with OA of the knee. ...
Apr 2, 2014
BURLINGTON, Mass., April 2, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present an overview of the company at the 13th Annual Needham Healthcare Conference. Dr. Clayman's presentation is scheduled for April 9, 2014, at 1:40 p.m. Eastern Time. The conference will take place A...
Mar 27, 2014
- Strong cash position bolstered with additional $75 million from IPO -- Lead drug candidate, FX006, planned to enter into confirmatory Phase 2b trial in osteoarthritis of the knee - - Second clinical candidate, FX007, expected to enter Phase 2 proof-of-concept trial later in 2014 - BURLINGTON, Mass., March 27, 2014 (GLOBE NEWSWIRE) -- Flex...
Mar 20, 2014
BURLINGTON, Mass., March 20, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its year-end 2013 financial results on Thursday, March 27, 2014, at 4 p.m. ET. The dial-in number for the conference call is (855) 770-0022 for domestic participants and (908) 9...
Feb 26, 2014
BURLINGTON, Mass., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present an overview of the company at the 34th Annual Cowen Health Care Conference. Dr. Clayman's presentation is scheduled for March 3, 2014, at 4:50 p.m. Eastern Time. The Conference will take place Ma...
Feb 18, 2014
BURLINGTON, Mass., Feb. 18, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today the closing of its initial public offering of 5,750,000 shares of its common stock at an initial public offering price of $13.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 750,000 ad...
Feb 11, 2014
BURLINGTON, Mass., Feb. 11, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today the pricing of its initial public offering of 5,000,000 shares of common stock at a price to the public of $13.00 per share. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "FLXN" on February 12...
FirstPrevious ...
11
NextLast
= add release to Briefcase